Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.55 |
| ▸ | PYGM | P11217 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TK2 | O00142 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774263 | 0.89 | RNASE1 (0.68) | TK1SLC6A2RNASE1LMNATK2 | |
| SCHEMBL14681227 | 0.89 | RNASE1 (0.68) | TK1SLC6A2RNASE1LMNATK2 | |
| SCHEMBL16287348 | 0.89 | RNASE1 (0.68) | TK1SLC6A2RNASE1LMNATK2 | |
| SCHEMBL767324 | 0.89 | RNASE1 (0.68) | TK1SLC6A2RNASE1LMNATK2 | |
| SCHEMBL12712226 | 0.89 | TK1 (0.67) | TK1SLC6A2RNASE1PYGMLMNA | |
| SCHEMBL1566532 | 0.89 | TK1 (0.67) | TK1SLC6A2RNASE1PYGMLMNA | |
| SCHEMBL1566533 | 0.89 | TK1 (0.67) | TK1SLC6A2RNASE1PYGMLMNA | |
| SCHEMBL13314169 | 0.89 | TK1 (0.67) | TK1SLC6A2RNASE1PYGMLMNA | |
| SCHEMBL11577542 | 0.88 | SLC6A2 (0.61) | TK1SLC6A2RNASE1TK2 | |
| SCHEMBL11577543 | 0.88 | SLC6A2 (0.61) | TK1SLC6A2RNASE1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874752-B2 | MIBG analogs and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200046861-A1 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2020-02-13 | — | — | US | disclosed |
| US-20180256761-A1 | MIBG ANALOGS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-09-13 | — | — | US | disclosed |
| EP-3352746-A1 | MIBG ANALOGS AND USES THEREOF | Board of Regents of the University of Nebraska (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170151355-A1 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2017-06-01 | — | — | US | disclosed |
| WO-2017053834-A1 | MIBG ANALOGS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2017-03-30 | — | — | WO | disclosed |
| US-9315534-B2 | Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120269725-A1 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER | US ARMY, SECRETARY OF THE ARMY | 2012-10-25 | — | — | US | disclosed |
| US-20090117041-A1 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents | US ARMY, SECRETARY OF THE ARMY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874752-B2 | MIBG analogs and uses thereof | SLC6A2, SLC18A2, SLC18A3 | TK1 212/4885SLC6A2 1/4885RNASE1 1773/4885 |
| US-20180256761-A1 | MIBG ANALOGS AND USES THEREOF | SLC6A2, SLC18A2, SLC18A3 | TK1 212/4885SLC6A2 1/4885RNASE1 1773/4885 |
| US-20200046861-A1 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER | NTPCR, BCHE, DUT | TK1 19/4885SLC6A2 1176/4885RNASE1 899/4885 |
| US-20090117041-A1 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents | TYMP, UMPS, TYMS | TK1 17/4885SLC6A2 760/4885RNASE1 3787/4885 |
| US-20120269725-A1 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER | NTPCR, TYMP, DUT | TK1 34/4885SLC6A2 1567/4885RNASE1 1138/4885 |
| US-20170151355-A1 | TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER | NTPCR, TYMP, DUT | TK1 34/4885SLC6A2 1567/4885RNASE1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.